Ultragenyx Pharmaceutical Inc. 8-K

What Happened

• On January 12, 2026, Ultragenyx Pharmaceutical Inc. (RARE) filed a Form 8‑K (Item 2.02) furnishing a press release that announced preliminary unaudited fiscal year 2025 results. The release summarizes total revenue for FY2025, revenue for Crysvita® and Dojolvi®, and the Company’s cash and investments at fiscal year‑end. Ultragenyx said it expects to report its full audited FY2025 results in February 2026.

Key Details

• Filing date: January 12, 2026 (Form 8‑K, Item 2.02); press release furnished as Exhibit 99.1.
• The press release provides preliminary, unaudited FY2025 totals for: overall revenue, Crysvita® revenue, Dojolvi® revenue, and year‑end cash & investments.
• Full year (audited) FY2025 financial results will be released in February 2026.
• The Form 8‑K was signed by Howard Horn, Executive VP & CFO.

Why It Matters

• This filing gives investors an early, unaudited view of Ultragenyx’s 2025 revenue performance and liquidity ahead of the formal February results — useful for gauging product trends (Crysvita, Dojolvi) and near‑term financial health.
• Because the figures are preliminary and unaudited, investors should wait for the full FY2025 report in February for confirmed, audited numbers and any accompanying management commentary or guidance.